Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

lCept in the treatment of autoimmune indications and any future products for our targeting indications may be greater than anticipated; the risk that we may not sustain our profitability; our ability to attract and retain collaborations relating to the development and commercialization of new indications; competition from other pharmaceutical or biotechnology companies; our ability to raise additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; economic and capital market conditions; our ability to obtain and protect patents and other intellectual property rights; our ability to operate without infringing the intellectual property rights of others; our ability to comply with applicable governmental regulations and standards; currency exchange rates; and our ability to successfully attract and retain skilled and experienced personnel.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities regulatory authorities in Canada at http://www.sedar.com. Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of n
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/26/2014)... 2014 SynCardia Systems, Inc., manufacturer of the ... Inc. 5000 named by the business magazine Inc. ... Health Canada and CE approved Total Artificial Heart, which ... heart transplant," says Michael P. Garippa , SynCardia,s ... care for patients dying from end-stage biventricular heart failure." ...
(Date:8/26/2014)... LONDON , August 26, 2014 ... ( http://www.fdna.com ) and London Medical Databases Ltd. ( ... offer, for the first time, online access to the ... FDNA, developer of the Facial Dysmorphology Novel Analysis ... Face2Gene [ TM ] , the only ...
(Date:8/26/2014)... , Aug. 26, 2014 Novira Therapeutics, ... for curative treatment of chronic hepatitis B virus (HBV) ... M.D., F.A.C.P., was appointed the Chair of its Scientific ... function as a Senior Advisor to the Company.  ... our SAB as Chair," said Christian Schade , ...
Breaking Medicine Technology:Inc. Magazine Ranks SynCardia Systems in Top 3rd in its 2014 Inc. 5000 List 2FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 2FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 3Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 3Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 4
... Neuralstem, Inc. (NYSE Amex: CUR ) announced ... Phase I safety trial of Neuralstem,s human spinal cord ... Lou Gehrig,s disease), and unpaid Neuralstem consultant, presented interim ... reported yesterday at the American Academy of Neurology (AAN ...
... April 12, 2011 Lanx®, Inc., a privately held ... devices for spinal surgery, today announced the initial launch ... clearance in February. The announcement was made at the ... Denver, CO. The Durango system is ...
Cached Medicine Technology:Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 4Lanx®, Inc. Launches Durango™ Stand-Alone ALIF System 2
(Date:8/27/2014)... 27, 2014 A recently published ... importance of time in correcting coagulopathy to prevent permanent ... variety of anticoagulants and examines medical conditions alleged to ... research, although anticoagulants have been approved by the FDA ... they are also known to affect the consistency of ...
(Date:8/27/2014)... Hospitals and health systems can have ... one they add brings the challenge of additional integration ... manage. Kaweah Delta Health Care District is moving in ... vendors who offer full-featured solutions that are easy to ... Delta selected Access to provide electronic forms and ...
(Date:8/27/2014)... In My Solitude, a leader in luxe self-care products, ... number of women from college students and busy moms to ... at the same time. , The Journey Candle Collection, a ... to help women stay focused on a specific task, moment ... candle and enjoy the fragrance. , “When setting a ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 PCOS ... women and puts them at risk for a number ... not widely known or well understood even within the ... as excess body hair (hirsutism) and excess body fat ... not aware that their problems are caused by PCOS. ...
(Date:8/27/2014)... Janice Holly Booth didn’t choose to travel ... her on an adventure outing to southern Utah where she’d ... harnesses and rappelling into mysterious, dark and potentially dangerous canyons. ... not my last,” she says. “I travelled alone for more ... edge, and experienced first-hand the kind of fear that keeps ...
Breaking Medicine News(10 mins):Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:Kaweah Delta Health Care District Selects Access to Provide Paperless E-Forms and Electronic Patient Signatures 2Health News:Kaweah Delta Health Care District Selects Access to Provide Paperless E-Forms and Electronic Patient Signatures 3Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 3Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 4Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 5Health News:Best-selling Author Janice Holly Booth Offers Tips to Navigating Fear and Living a Fuller Life 2
... Physical activity is an important health behaviour for ... has been understudied and underappreciated. This book, edited ... explores in depth the relation between physical activity ... treatments, recovery after treatments, long-term survivorship, secondary prevention, ...
... shown for the first time that damage to a particular ... are associated with multiple sclerosis. The study is available ... processes in MS are not well understood, but an important ... cells involved in immune defense through the blood-brain barrier. ...
... use to compensate for the turbulence of the atmosphere ... an artificial star called a guide star and use ... Lihong Wang, PhD, the Gene K. Beare Distinguished ... Louis, has invented a guide star for biomedical rather ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, Feb. ... better than aspirin for stroke prevention in some patients ... as atrial fibrillation, according to research presented Thursday. ... use by the U.S. Food and Drug Administration. But ...
... SAN FRANCISCO (February 11, 2011) In a study to ... annual meeting, The Pregnancy Meeting , in San Francisco, researchers ... risk for preterm birth participated in a preterm birth prevention ... fewer cases of infant morbidity. The National Center for ...
... Reporter , THURSDAY, Feb. 10 (HealthDay News) -- While ... also hold true: More than one-quarter of married Americans ... has strengthened their union. University of Virginia researchers ... for 29 percent of the people surveyed. Among those ...
Cached Medicine News:Health News:Researchers find reduced levels of an important neurotransmitter in MS 2Health News:A guide star lets scientists see deep into human tissue 2Health News:A guide star lets scientists see deep into human tissue 3Health News:A guide star lets scientists see deep into human tissue 4Health News:A guide star lets scientists see deep into human tissue 5Health News:A guide star lets scientists see deep into human tissue 6Health News:New Drug May Help Patients With Irregular Heartbeat Avoid Stroke 2Health News:New Drug May Help Patients With Irregular Heartbeat Avoid Stroke 3Health News:Study finds preterm birth clinic attendence leads to major reduction in infant disability 2Health News:Recession Strengthens Some Marriages: Survey 2Health News:Recession Strengthens Some Marriages: Survey 3
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
Direct antigen rapid immunoassay for the detection of Shiga toxin-producing E. coli 0157, which aids in the diagnosis of E. coli 0157:H7 infection...
... The Directigen™ Meningitis Individual Tests ... tests for the direct qualitative ... influenzae type b, S. pneumoniae, ... Escherichia coli K1 in cerebrospinal ...
... A revolutionary new agar plate for economically screening ... this biplate with the urine specimen. If the ... the chromogenic side of the biplate will 3 ... E. coli, the BluEcoli™ Urine Biplate is a ...
Medicine Products: